Morepen Laboratories Ltd Q4 FY25 Earnings Analysis
Published 25 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹4.2K Cr
Price
₹84.2
Market Cap
₹4.2K Cr
P/E Ratio
35.9
Revenue Rank
Margin Rank
Earnings Summary
The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
📊 Revenue & Sales Performance
Rank 3- →The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27.
- →Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment.
- →API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues.
- →Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business.
- →Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to deliver strong growth given health awareness trends.
- →The new molecule contribution in API is rising, forecasting faster growth in this segment.
- →Expansion in manpower, particularly medical representatives (from 200 to 1,200 over 3 years), is expected to drive formulation sales growth.
- →Long-term EBITDA growth is expected, linked to product mix improvements, exports, and capacity increases.
📈 Profitability & Margins
Rank 3- →The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
- →EBITDA is expected to increase, particularly due to product mix improvements:
- → - API business EBITDA to grow with capacity expansion and increased exports.
- → - Finished dosage (formulations) business has higher margins (around 70%) compared to API (30-40%) and is expected to improve EBITDA, with some investment phase in initial years.
- → - Medical devices segment continues consistent volume growth, boosting EBITDA.
- →Operating expenses are being tightly controlled amid lower sales realizations.
- →With capacity expansion (e.g., API capacity doubled to 600 KL expected by FY '26 end) and increased outsourcing partnerships, revenues and margins are projected to improve.
- →Overall, improvements in revenue, EBITDA, and PAT margins are anticipated through strategic product and market focus.
🏗️ Capital Expenditure Plans
Yes- →Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26.
- →After the 600 KL capacity expansion, there are no immediate plans for further capacity increases.
- →The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes.
- →Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins.
- →There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S. via Amazon.
- →R&D investments continue with 55 scientists, 168 patents filed, and development of new molecules to drive future growth.
💰 Fundraising & Capital Structure
No information- →There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
- →The company is focused on organic growth through capacity expansion (e.g., completing 600 KL API capacity by FY '26).
- →Discussions emphasize revenue growth, margin improvement, and operational efficiencies rather than funding needs.
- →No comments were made about raising capital to fund these expansions or for any other purposes.
- →The management's strategy indicates reliance on internal resources, customer partnerships, and outsourcing rather than external fundraising.
- →No specific plans or intentions to issue new equity or take on additional debt were disclosed during the call.
📋 Order Book & Pipeline
No- →The company has 600 KL capacity planned for FY '26, expected to be completed within the year.
- →Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted).
- →They are working on building a good outsourcing partner network to manage excess demand or capacity shortage.
- →Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake.
- →Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues.
- →Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to recent raw material price increases and global market conditions.
- →They are ready to compromise on revenue short term (1-2 months or quarters) but will not go below certain price levels.
- →Confident that API prices have almost bottomed out, implying a more stable orderbook and pricing environment ahead.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Morepen Laboratories Ltd Q4 FY25 results?
The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 35.9 with a market cap of ₹4,216 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26. - After the 600 KL capacity expansion, there are no immediate plans for further capacity increases. - The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes. - Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins. - There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.